The next "Ozempic" like product in aesthetics? Findell Capital flags $ESTA:US as a multibagger

SumZero CEO Divya Narendra recently sat down with Brian Finn, the top-ranked healthcare analyst on SumZero platform and CIO and Founder of Findell Capital. In this episode, we delve into ESTA, a Costa Rican-based breast implant manufacturer that's about to make waves in the U.S. market with its groundbreaking products, Motiva and MiaFemTech. Discover why ESTA's innovative implants are considered best-in-class for safety and efficacy, the historical context of breast implants, and why there's significant investor interest now. Learn more about the company's market position, growth potential, and future plans, including the anticipated FDA approval and expansion into the U.S. market. Perfect for anyone interested in emerging medtech investment opportunities. Don't miss out on this in-depth analysis and expert insights.

Brian has shared more than 20 of his highest conviction theses on SumZero over the years. Those ideas, on average, have outperformed their respective benchmarks by greater than 30%, to date. To review all of his work, www.sumzero.com/apply.

00:00 Introduction to the Interview
00:37 Overview of ESTA and Its Innovations
01:23 Market Expansion and FDA Approval
02:17 Challenges and Market Potential
03:17 History and Development of Breast Implants
09:24 ESTA's Market Share and Sales Projections
10:21 Product Differentiation and Patent Protection
22:42 MIA FemTech: A Revolutionary Procedure
31:30: Refuting Hindenburg's short
35:20 Financial Health and Future Growth
41:24 Conclusion and Final Thoughts

Investment Disclaimer:
The information provided herein is for informational purposes only and should not be construed as investment advice, an endorsement, or a solicitation to buy or sell any securities or financial instruments. Investing in securities involves risks, including the potential loss of principal. Past performance is not indicative of future results.
Any opinions, analyses, forecasts, projections, or other statements regarding future prospects of companies, sectors, or the market as a whole constitute the subjective views of the authors or contributors as of the date of preparation and are subject to change without notice. The accuracy, completeness, or reliability of the information cannot be guaranteed.
Investors should conduct their own research and consult with a qualified investment professional before making any investment decisions. All investment decisions are the responsibility of the individual investor and should be made based on the investor's own objectives, risk tolerance, and financial circumstances.
No representation or warranty, express or implied, is made regarding the accuracy or completeness of the information contained herein, and no liability shall be accepted for any direct, indirect, or consequential losses or damages arising from the use of this information or reliance on any statements contained herein.
Investing in securities involves significant risks, including the potential loss of principal. Investors should carefully consider their investment objectives, risk tolerance, and time horizon before investing. Diversification does not ensure a profit or protect against loss in a declining market.

Видео The next "Ozempic" like product in aesthetics? Findell Capital flags $ESTA:US as a multibagger канала SumZero